Cyber Monday saleUp to 70% OFF
AAA

Herantis Pharma Plc

No trades
See on Supercharts
Overview
Financials Discussions Forecast Seasonals

A1158V chart


Full chart

A1158V upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪25.60 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.0146 EUR
Net income (FY)
‪279.84 K‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪15.24 M‬
Beta (1Y)
−0.32

Employees


Employees (FY)
10
Change (1Y)
0
Revenue / Employee (1Y)
0.00 EUR
Net income / Employee (1Y)
‪30.89 K‬ EUR

About Herantis Pharma Plc


Sector
Health Technology
CEO
Antti Vuolanto
Headquarters
Espoo
Website
herantis.com
Founded
2008
ISIN
FI4000087861
FIGI
Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. It offers medicinal products such as Cis-UCA eye drops for dry eye, CDNF for Parkinson's disease, Lymfactin for secondary lymphedema, Cis-UCA emulsion cream for atopic dermatitis, and CDNF for amyotrophic lateral sclerosis (ALS). The company was founded by Eero Hemminki Castren, Henri Juhani Huttunen, Heikki Rauvala, and Mart Saarma in 2008 and is headquartered in Espoo, Finland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on LS exchange Herantis Pharma Plc stocks are traded under the ticker A1158V.
We've gathered analysts' opinions on Herantis Pharma Plc future price: according to them, A1158V price has a max estimate of 2.20 EUR and a min estimate of 2.20 EUR. Watch A1158V chart and read a more detailed Herantis Pharma Plc stock forecast: see what analysts think of Herantis Pharma Plc and suggest that you do with its stocks.
Yes, you can track Herantis Pharma Plc financials in yearly and quarterly reports right on TradingView.
Herantis Pharma Plc is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
A1158V earnings for the last half-year are −0.14 EUR per share, whereas the estimation was −0.12 EUR, resulting in a −13.92% surprise. The estimated earnings for the next half-year are −0.12 EUR per share. See more details about Herantis Pharma Plc earnings.
Herantis Pharma Plc revenue for the last half-year amounts to ‪5.00 K‬ EUR, despite the estimated figure of 0.00 EUR. In the next half-year revenue is expected to reach ‪5.00 K‬ EUR.
A1158V net income for the last half-year is ‪−2.69 M‬ EUR, while the previous report showed ‪2.08 M‬ EUR of net income which accounts for −229.49% change. Track more Herantis Pharma Plc financial stats to get the full picture.
No, A1158V doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 5, 2024, the company has 10.00 employees. See our rating of the largest employees — is Herantis Pharma Plc on this list?
Like other stocks, A1158V shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Herantis Pharma Plc stock right from TradingView charts — choose your broker and connect to your account.